STOCK TITAN

Esperion Therapeutics (ESPR) Stock News

ESPR

Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.

Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.

Rhea-AI Summary

Esperion (ESPR) has reached a settlement with Aurobindo Pharma restricting U.S. marketing of generic NEXLETOL and NEXLIZET before April 19, 2040.

The agreement covers Aurobindo and an affiliate and resolves Esperion’s patent litigation against them over applications seeking approval for generic versions before the applicable patents expire. NEXLETOL contains bempedoic acid; NEXLIZET combines bempedoic acid and ezetimibe. Aurobindo’s commitment is subject to certain limited circumstances customarily included in such agreements.

Patent litigation involving MSN Pharmaceuticals and an affiliate, and Sandoz, remains ongoing. There is no assurance that those proceedings will prevent U.S. marketing of generic NEXLETOL and/or NEXLIZET before April 19, 2040. The settlement therefore does not resolve all remaining generic-entry litigation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Esperion (ESPR) entered into a settlement agreement with Renata and an affiliate restricting U.S. marketing of generic NEXLETOL and NEXLIZET.

Renata agreed not to market generic versions of either drug before April 19, 2040, unless certain limited circumstances customarily included in these agreements occur. The agreement resolves Esperion’s patent litigation against Renata over its Abbreviated New Drug Applications, applications seeking approval to market generic medicines before the applicable patents expire. Renata is the sixth filer to reach a settlement.

Patent litigation remains ongoing against Aurobindo Pharma and an affiliate, MSN Pharmaceuticals and an affiliate, and Sandoz. The outcome remains uncertain, including whether generic versions of either medicine could enter the U.S. market before April 19, 2040.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Esperion Therapeutics (ESPR) is launching a nationwide awareness effort for ENBUMYST, a short-term nasal diuretic for edema associated with congestive heart failure. Edema is swelling caused by excess fluid. ENBUMYST delivers bumetanide through a single-use nasal spray and offers an at-home treatment option for appropriate patients.

Esperion has acquired ENBUMYST, adding an intranasal route of administration to its portfolio. Its awareness initiatives include educational materials for clinicians, patients and caregivers, participation in heart-failure medical meetings, and partnerships with patient and professional organizations. The company is also initiating data-generation activities to support ENBUMYST use in heart failure treatment. The effort comes ahead of the CMS Ambulatory Specialty Model, a mandatory value-based payment model scheduled to begin January 1, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Esperion (NASDAQ: ESPR) presented new bempedoic acid data at the European Atherosclerosis Society Congress 2026. A Phase 2 CLEAR Path 1 study in children aged 6-17 with heterozygous familial hypercholesterolemia showed weight-based dosing achieved adult-like exposure and LDL-C reductions of about 6-25% without new safety signals.

A CLEAR Outcomes post hoc analysis in statin-intolerant adults found 42% of bempedoic acid patients achieved ≥30% LDL-C reduction at 3 months, with greater response linked to female sex, higher baseline LDL-C and concurrent ezetimibe use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) granted 260,000 restricted stock units (RSUs) on May 12, 2026 to 23 new employees under its 2017 Inducement Equity Incentive Plan, used exclusively for new hires under NASDAQ Rule 5635(c)(4).

RSUs vest 25% after one year, then 75% in twelve quarterly installments, subject to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced two new analyses and three encore presentations on bempedoic acid to be featured at the European Atherosclerosis Society (EAS) Congress 2026, May 24-27 in Athens.

Data include a Phase 2 pediatric HeFH study showing LDL-C reductions and CLEAR Outcomes analyses of factors linked to ≥30% LDL-C lowering and cardiovascular outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
News
Rhea-AI Summary

Esperion (Nasdaq: ESPR) agreed to be acquired by funds managed by ARCHIMED for up to approximately $1.1 billion in total equity value on a fully diluted basis. Shareholders will receive $3.16 per share in cash at closing plus a non-tradeable CVR for up to $100 million in contingent milestone payments tied to future U.S. net sales. The upfront cash equals a 58% premium to the April 30, 2026 closing price. The transaction, unanimously approved by the board, is expected to close in Q3 2026, subject to shareholder and regulatory approvals, after which Esperion will become private and its Nasdaq listing will end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.50%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will report first quarter 2026 financial results before the market opens on May 7, 2026.

Management will host a live webcast at 8:00 a.m. ET the same day to discuss results and business updates; a replay will be available about two hours after the call and archived for ~90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
earnings date
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) closed its acquisition of Corstasis Therapeutics on April 2, 2026, adding Enbumyst, the first and only FDA‑approved nasal spray loop diuretic. Enbumyst received FDA approval in September 2025 for edema associated with congestive heart failure, hepatic, and renal disease.

The acquisition expands Esperion’s cardiovascular franchise into outpatient, acute‑adjacent care and aims to leverage existing commercial infrastructure to accelerate adoption, payer engagement, and patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.30%
Tags
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 9:30 a.m. ET, with a live webcast available on the company investor site. A replay will be posted about two hours after the call and archived for ~90 days.

Esperion is a commercial-stage cardiometabolic biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with approvals in more than 40 countries and an R&D pipeline targeting ACLY biology, Primary Sclerosing Cholangitis, and renal diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
none

FAQ

What is the current stock price of Esperion Therapeutics (ESPR)?

Esperion Therapeutics (ESPR) last closed at $3.18.